Measurement of Ion Transport Function in Rectal Biopsies

Methods in Molecular Biology

Volumn 741, Issue , 2011, Pages 87-107

  Hug, Martin J ^a   Derichs, Nico ^b,c   Bronsveld, Inez ^d   Clancy, Jean Paul ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e University of Alabama at Birmingham   (United States)

Author keywords

CFTR; cystic fibrosis; electrolyte transport; Epithelial cells; Ussing chamber

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BIOPSY; CYSTIC FIBROSIS; DRUG DEVELOPMENT; ELECTRIC CONDUCTIVITY; ELECTROPHYSIOLOGY; HUMAN; ION TRANSPORT; METABOLISM; METHODOLOGY; PATHOLOGY; RECTUM;

BIOPSY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; ELECTRIC CONDUCTIVITY; ELECTROPHYSIOLOGY; HUMANS; ION TRANSPORT; RECTUM;

EID: 80052320123     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-117-8_7     Document Type: Chapter

References (59)

1. Reid, E. W. (1889) Report on experiments upon “absorption without osmosis”. Brit. Med. J. 1, 323–326.
2. Reid, E. W. (1901) Transport of fluid by certain epithelia. J. Physiol. 26(6), 436–444.
3. Levi, H., and Ussing, H. H. (1949) Resting potential and ion movements in the frog skin. Nature 164, 928.
4. Koefoed-Johnsen, V., and Ussing, H. H. (1958) The nature of the frog skin potential. Acta Physiol. Scand. 42, 298–308.
5. Ussing, H. H., and Zerahn, K. (1951) Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiol. Scand. 23, 110–127.
6. Kottra, G., Weber, G., and Frömter, E. (1989) A method to quantify and correct for edge leaks in Ussing chambers. Pflügers Archiv. Eur. J. Physiol. 415, 235–240.
7. Gitter, A. H., Schulzke, J. D., Sorgenfrei, D., and Fromm, M. (1997) Ussing chamber for high-frequency transmural impedance analysis of epithelial tissues. J. Biochem. Biophys. Methods 35, 81–88.
8. Singh, A. K., Singh, S., Devor, D. C., Frizzell, R. A., Driessche, W. V., Bridges, R. J. (2002) Transepithelial impedance analysis of chloride secretion, in (William R. S., ed.), Cystic fibrosis methods and protocols, Vol. 70, pp. 129–142. Humana Press Inc., Totowa, NJ, USA.
9. Kunzelmann, K., and Mall, M. (2002) Electrolyte transport in the mammalian colon: Mechanisms and implications for disease. Physiol. Rev. 82, 245–289.
10. Gitter, A. H., Bendfeldt, K., Schulzke, J. D., and Fromm, M. (2000) Trans/paracellular, surface/crypt, and epithelial/subepithelial resistances of mammalian colonic epithelia. Pflügers Arch. 439, 477–482.
11. Debongnie, J. C., and Phillips, S. F. (1978) Capacity of the human colon to absorb fluid. Gastroenterology 74, 698–703.
12. + channel is made of three homologous subunits. Nature 367, 463–467.
13. Heitzmann, D., and Warth, R. (2008) Physiology and pathophysiology of potassium channels in gastrointestinal epithelia. Physiol. Rev. 88, 1119–1182.
14. Schroeder, B. C., Waldegger, S., Fehr, S., Bleich, M., Warth, R., Greger, R., et al. (2000) A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 403, 196–199.
15. + secretion through multiple KCa-type channels and regulation by IKCa channels in rat proximal colon. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G185–196.
16. Butterfield, I., Warhurst, G., Jones, M. N., and Sandle, G. I. (1997) Characterization of apical potassium channels induced in rat distal colon during potassium adaptation. J. Physiol. 501, 537–547.
17. – secretion. Acta Physiol. 189, 251–258.
18. Sausbier, M., Matos, J. E., Sausbier, U., Beranek, G., Arntz, C., Neuhuber, W., et al. (2006) Distal colonic K(+) secretion occurs via BK channels. J. Am. Soc. Nephrol. 17, 1275–1282.
19. Quinton, P., and Bijman, J. (1983) Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N. Engl. J. Med. 308, 1185–1189.
20. Greger, R. (2000) Role of CFTR in the colon. Annu. Rev. Physiol. 62, 467–491.
21. Russo, M. A., Hogenauer, C., Coates, S. W., Santa Ana, C. A., Porter, J. L., Rosenblatt, R. L., et al. (2003) Abnormal passive chloride absorption in cystic fibrosis jejunum functionally opposes the classic chloride secretory defect. J. Clin. Invest. 112, 118–125.
22. Catalán, M., Niemeyer, M. I., Cid, L. P., and Sepúlveda, F. V. (2004) Basolateral ClC-2 chloride channels in surface colon epithelium: Regulation by a direct effect of intracellular chloride. Gastroenterology 126, 1104–1114.
23. Traynor, T. R., and O’Grady, S. M. (1992) Mechanisms of Na and Cl absorption across the distal colon epithelium of the pig. J. Comp. Physiol. B 162, 47–53.
24. – secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G753–764.
25. Lucas, M. L. (2008) Enterocyte chloride and water secretion into the small intestine after enterotoxin challenge: Unifying hypothesis or intellectual dead end? J. Physiol. Biochem. 64, 69–88.
26. Veeze, H. J., Sinaasappel, M., Bijman, J., Bouquet, J., and de Jonge, H. R. (1991) Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 101, 398–403.
27. Mall, M., Bleich, M., Schürlein, M., Kühr, J., Seydewitz, H. H., Brandis, M., Greger, R., and Kunzelmann, K. (1998) Cholinergic ion secretion in human colon requires coactiva-tion by cAMP. Am. J. Physiol. Gastrointest. Liver Physiol. 275, G1274–1281.
28. Mall, M., Hirtz, S., Gonska, T., and Kunzelmann, K. (2004) Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J. Cyst. Fibros. 3, 165–169.
29. – channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 127, 1085–1095.
30. Derichs, N., Knoll, J., Hyde, R., Pedemonte, N., Galietta, L. V., and Ballmann, M. (2009) Preclinical evaluation of CFTR modulators in ex vivo human rectal tissue. Pediatr. Pulmonol. 44, 292.
31. de Jonge, H. R., Ballmann, M., Veeze, H. J., Bronsveld, I., Stanke, F., Tümmler, B., et al. (2004) Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J. Cyst. Fibros. 3, 159–163.
32. Stanke, F., Ballmann, M., Bronsveld, I., Dörk, T., Gallati, S., Laabs, U., et al. (2008) Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. J. Med. Genet. 45, 47–54.
33. Du, M., Jones, J. R., Lanier, J., Keeling, K. M., Lindsey, J. R., Tousson, A., et al. (2002) Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene. J. Mol. Med. 80, 595–604.
34. Du, M., Keeling, K. M., and Fan, L. (2006) Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J. Mol. Med. 84, 573–582.
35. Du, M., Liu, X., Welch, E. M., Hirawat, S., Peltz, S. W., and Bedwell, D. M. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc. Natl. Acad. Sci. USA 105, 2064–2069.
36. Du, M., Keeling, K. M., Fan, L., Liu, X., and Bedwell, D. M. (2009) Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J. Biol. Chem. 284, 6885–6892.
37. Clancy, J. P., Rowe, S. M., Bebok, Z., Aitken, M. L., Gibson, R., Zeitlin, P., et al. (2007) No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am. J. Respir. Cell Mol. Biol. 37, 57–66.
38. Davidson, H., Wilson, A., Gray, R. D., Horsley, A., Pringle, I. A., McLachlan, G., et al. (2009) An immunocytochemical assay to detect human CFTR expression following gene transfer. Mol. Cell. Probes 23, 272–280.
39. Harris, C. M., Mendes, F., Dragomir, A., Doull, I. J., Carvalho-Oliveira, I., Bebok, Z., et al. (2004) Assessment of CFTR localisation in native airway epithelial cells obtained by nasal brushing. J. Cyst. Fibros. 3, 43–48.
40. Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433–1441.
41. Ma, T., Vetrivel, L., Yang, H., Pedemonte, N., Zegarra-Moran, O., Galietta, L. J., et al. (2002) High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J. Biol. Chem. 277, 37235–37241.
42. Yang, H., Shelat, A. A., Guy, R. K., Gopinath, V. S., Ma, T., Du, K., et al. (2003) Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J. Biol. Chem. 278, 35079–35085.
43. Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91.
44. Robert, R., Carlile, G. W., Pavel, C., Liu, N., Anjos, S. M., Liao, J., et al. (2008) Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol. Pharmacol. 73, 478–489.
45. Van Goor, F., Straley, K. S., Cao, D., González, J., Hadida, S., Hazlewood, A., et al. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L1117–1130.
46. Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Cao, D., Neuberger, T., et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825–18830.
47. Al-Nakkash, L., and Hwang, T. C. (1999) Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and-independent mechanisms. Pflugers Arch. 437, 553–561.
48. Hwang, T. C., Wang, F., Yang, I. C., and Reenstra, W. W. (1997) Genistein potentiates wild-type and delta F508-CFTR channel activity. Am. J. Physiol. 273, C988–998.
49. Wang, W., Bernard, K., Li, G., and Kirk, K. L. (2007) Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J. Biol. Chem. 282, 4533–4544.
50. Wang, W., Li, G., Clancy, J. P., and Kirk, K. L. (2005) Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. J. Biol. Chem. 280, 23622–23630.
51. Gibson, L. E., and Cooke, R. E. (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilo-carpine by iontophoresis. Pediatrics 23, 545– 549.
52. Knowles, M., Gatzy, J., and Boucher, R. (1981) Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med. 305, 1489–1495.
53. Veeze, H. J., Halley, D. J. J., Bijman, J., de Jongste, J. C., de Jonge, H. R., and Sinaasappel, M. (1994) Determinants of mild clinical symptoms in cystic fibrosis patients – Residual chloride secretion measured in rectal biopsies in relation to the genotype. J. Clin. Invest. 93, 461–466.
54. Bronsveld, I., Mekus, F., Bijman, J., Ballmann, M., Greipel, J., Hundrieser, J., et al (2000) Residual chloride secretion in intestinal tissue of DF508 homozygous twins and siblings with cystic fibrosis. Gastroenterology 119, 32–40.
55. Derichs, N., Mekus, F., Bronsveld, I., Bijman, J., Veeze, H. J., von der Hardt, H., et al. (2004) Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients. Pediatr. Res. 55, 69–75.
56. Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., et al. (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115, 2564–2571.
57. Amaral, M. D., and Kunzelmann, K. (2007) Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol. Sci. 28, 334–341.
58. Verkman, A. S., and Galietta, L. J. (2009) Chloride channels as drug targets. Nat. Rev. Drug Discov. 8, 153–171.
59. Rowe, S. M., Accurso, F., and Clancy, J. P. (2007) Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc. Am. Thorac. Soc. 4, 387–398.